期刊文献+

低剂量^(125)I内照射A549肺癌的抑瘤效果及对survivin和NF-κB表达影响的研究 被引量:4

下载PDF
导出
摘要 目的:观察低剂量125I持续内照射对裸鼠A549细胞肺癌的抑瘤效果和对survivin、NF-κB表达的影响,以期进一步探讨125I的抑瘤机制。方法:将25只裸鼠A549肺癌模型分为实验组(n=13)和对照组(n=12)。实验组用表观活度为5.55~7.03 MBq/粒的125I微粒子植入治疗,对照组用剂量为0的"冷粒子"进行对照实验。观察28 d,记录两组小鼠存活率、测量残存肿瘤的体积、重量并计算肿瘤体积抑制率;HE染色及survivin、NF-κB免疫组化检测,比较125I粒子对肿瘤组织的损伤情况及两组survivin和NF-κB的表达差异。结果:实验组和对照组小鼠存活率分别为84.6%和75.0%(P>0.05),平均肿瘤体积分别为(0.36±0.15)cm3和(0.42±0.12)cm3(P>0.05),肿瘤体积抑制率为14.3%。实验组见紧贴125I粒子周边变性坏死,稍远离部位及血管周围肿瘤细胞存活明显,对照组粒子周围肿瘤细胞生长良好。实验组survivin阳性表达率(76.9%)高于对照组(58.3%,P<0.05),NF-κB在两组皆有高表达(分别为92.3%和83.3%,P>0.05)。结论:低剂量125I持续内照射A549肺癌细胞的抑瘤效果不太明显,低剂量125I辐射可上调NF-κB、survivin等细胞凋亡相关蛋白的表达而可能与低剂量辐射损伤的适应性反应有关。
出处 《实用医学杂志》 CAS 北大核心 2013年第21期3492-3494,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献11

  • 1岳麓,桂律,陈红红,罗伟华,徐萍,刘伟琪,程文英.^(125)I植入对小鼠移植性实体瘤抑制效果[J].中华放射医学与防护杂志,2003,23(5):314-316. 被引量:7
  • 2钟伟邦,李园,李永平,武兆忠,符柳江.^(125)I粒子植入近距离治疗视网膜母细胞瘤小鼠移植瘤[J].实用医学杂志,2011,27(5):754-756. 被引量:3
  • 3岳麓,程文英,罗伟华,陈红红,刘伟琪.^(125)I籽源离体照射细胞平面剂量率分布研究[J].中华放射肿瘤学杂志,2005,14(5):435-438. 被引量:9
  • 4张占春,贾廷珍,朱应葆.低剂量照射诱导A549和2BS细胞适应性反应的研究[J].中华放射医学与防护杂志,2001,21(2):107-110. 被引量:7
  • 5Fan J, Wang L, Jiang G N, et al. The role of survivin on overallsurvival of non-small cell lung cancer, a meta-analysis ofpublished literatures[J]. Lung Cancer, 2008,61(1):91-96.
  • 6Xie Y L,An L, Jiang H, et al. Nuclear survivin expression isassociated with a poor prognosis in Caucasian non-small celllung cancer patients[J]. Clin Chim Acta, 2012,414(1):41-43.
  • 7Kanwar J R, Kamalapuram S K, Kanwar R K. KanwarTargetingsurvivin in cancer:the cell-signalling perspective[J]. DrugDiscov Today, 2011,16(11-12):485-494.
  • 8Capalbo G, Rodel C, Stauber R H, et al. The role of survivinfor radiation therapy. Prognostic and predictive factor andtherapeutic target[J]. Strahlenther Onkol,2007,183(11):593-599.
  • 9Gupta S C, Sundaram C, Reuter S, et al. Inhibiting NF-kBactivation by small molecules as a therapeutic strategy[J].Biochim Biophys Acta, 2010,1799(10-12):775-787.
  • 10Tang X, Liu D, Shishodiai S, et al. Nuclear factor-kappa B(NF-kappa B)is frequently expressed in lung cancer andpreneoplastic lesions[J]. Cancer, 2006,107(11):2637-2646.

二级参考文献28

  • 1张波,钟秀风,李永平,黄文革,聂莉,张文忻.视网膜母细胞瘤SO-RB_(50)瘤细胞NOD-SCID鼠皮下异位移植全身转移瘤模型的建立[J].国际眼科杂志,2005,5(4):638-642. 被引量:3
  • 2张欣,李亚明,张延军,季晓鹏,陶莉,张剑英,赵贞贞,朱毅,杨春,赵明,田爱娟.单次化疗后肿瘤内^99Tc^m-Annexin V的分布与bcl-2、bax蛋白表达的相关性研究[J].同位素,2007,20(1):36-40. 被引量:3
  • 3韦长元,杨伟萍,李挺,欧超,姚波.放射性粒子^(125)I对H_(22)肝癌细胞凋亡的研究[J].中华肿瘤防治杂志,2007,14(14):1070-1072. 被引量:5
  • 4Williamson JF, Coursey BM, Dewerd LA, et al. Guidence to users of Nycomed Amersham and North American Scientific, lnc, 1-125 interstitial sources: dosimetry and calibration changes: recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on Low-energy Seed Dosimetry. Med Phys. 1999,26 : 570-573.
  • 5Chen Y, Stanton RE, Hoist R J, et al. Treatment planning for prostate implant with loose seeds. Med Phys, 1997,24 : 1141-1145.
  • 6Kim JH, Hilaris BS. Iodine-125 source in interstitial tumor therapy. Radiology, 1975,123 : 163-169.
  • 7Grimm PD, Blasko JC, Sylvester JE, et al. lO-year biochemical (prostate specific antigen) control of prostate cancer with ^125l brachylherapy, Int J Radiat Oncol Biol Phys,2001,51 :31-40.
  • 8Ragde H, Korb LJ, Elgamal AA, et al. Modem prostate brachytherapy: postate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer, 2000,89 : 135-141.
  • 9Ragde H, Grado GL, Nadir BS. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol, 2001,54 : 739-747.
  • 10Chen A, Galloway M, Landreneau R, et al. lntraoperative 1-125 brachytherapy for high-risk stage 1 non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys, 1999,44: 1057-1063.

共引文献22

同被引文献15

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部